ABSTRACT
Hilar cholangiocarcinoma is the most common extrahepatic malignant tumor in clinic, accounting for about 50%-60% of bile duct tumors. Currently, radical surgical resection is regarded as the best treatment for early hepatic hilar cholangiocarcinoma, but, it’s early lesions have no obvious clinical symptoms. Most patients are already in the advanced stage of the disease when they are admitted to hospital. The surgical resection rate is low, and the 5-year survival rate does not exceed 25%. Locally advanced hepatic hilar cholangiocarcinoma are treated with neoadjuvant chemoradiation therapy followed by surgery, it can prolong survival time of the patient. At the same time, the recurrence rate after surgery can reach 50%-70%, and the cancer easily invades microvessels, lymphatic vessels, peripheral nerves and liver, which is one of the most challenging problems in the field of biliary surgery. Therefore, early diagnosis, perioperative management, adequate and accurate preoperative staging assessment, intraoperative standardized resection, postoperative adjuvant therapy of hilar cholangiocarcinoma, it is of great significance to improve the rate of radical surgical resection and prolong the survival time of patients.
ABSTRACT
Intrahepatic cholangiocarcinoma (ICC) has a poor prognosis. Surgical treatment combined with adjuvant therapy including chemotherapy, radiotherapy, molecular targeted drug therapy, local liver damage therapy, interventional therapy, antiviral therapy can have complementary effects to prevent its recurrence after surgery. We will review the latest advances in surgery and adjuvant therapy for ICC, and provide new ideas for the comprehensive treatment and clinical research of ICC.
ABSTRACT
Intrahepatic cholangiocarcinoma (ICC) has a poor prognosis.Surgical treatment combined with adjuvant therapy including chemotherapy,radiotherapy,molecular targeted drug therapy,local liver damage therapy,interventional therapy,antiviral therapy can have complementary effects to prevent its recurrence after surgery.We will review the latest advances in surgery and adjuvant therapy for ICC,and provide new ideas for the comprehensive treatment and clinical research of ICC.
ABSTRACT
Hepatolithiasis is a very common hepatobiliary disease in Asia. Recurrent hepatolithiasis frequently lead to incidence of intrahepatic cholangiocarcinoma. The associated intrahepatic cholangiocarci-noma is generally hidden and often covered up by the related clinical symptoms caused by stones, which can easily lead to missed the best time of diagnosisand treatment. This paper mainly showed the diseases of intra-hepatic cholangiocarcinoma associated with intrahepatic cholelithiasis, and expounded the changes of local microenvironment of bile duct tissue from intrahepatic cholelithiasis to intrahepatic cholangiocarcinoma. The purpose of this study is to look for the risk factors related to the development of intrahepatic cholelithiasis to intrahepatic cholangiocarcinoma and to provide a new research direction for the clinical treatment of intrahe-patic cholangiocarcinoma.